Adage Capital Partners
CGEM icon

Adage Capital Partners’s Cullinan Oncology CGEM Stock Holding History

Adage Capital Partners’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.33M Buy
+238,000
New +$3.53M 0.01% 823
2025
Q1 		– Sell
-1,030,438
Closed -$12.6M – 858
2024
Q4 		$12.6M Sell
1,030,438
-325,438
-24% -$4.68M 0.02% 548
2024
Q3 		$22.7M Sell
1,355,876
-876,953
-39% -$15.6M 0.04% 423
2024
Q2 		$38.9M Buy
2,232,829
+1,282,829
+135% +$27.3M 0.07% 269
2024
Q1 		$16.2M Buy
+950,000
New +$14.7M 0.03% 506
2023
Q4 		– Sell
-1,150,000
Closed -$10.4M – 869
2023
Q3 		$10.4M Hold
1,150,000
– – 0.02% 553
2023
Q2 		$12.4M Buy
+1,150,000
New +$12.2M 0.03% 525
2021
Q3 		– Sell
-78,000
Closed -$2.01M – 1027
2021
Q2 		$2.01M Sell
78,000
-263,731
-77% -$8.11M ﹤0.01% 880
2021
Q1 		$14.2M Buy
+341,731
New +$13.9M 0.03% 569

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Adage Capital Partners's CGEM Position: Q2 2026 in Review

Adage Capital Partners opened a new position in Cullinan Oncology (CGEM) in Q2 2026: 238,000 shares worth $4.33M. The stake represents 0.01% of the portfolio and ranks #823 among its holdings. This is a return to the name: Adage Capital Partners previously reported a position in CGEM as recently as Q4 2024.

Adage Capital Partners first reported a position in CGEM in Q1 2021 and has held it in 9 quarters since. The position peaked at $38.9M in Q2 2024. 183 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Adage Capital Partners held 238,000 shares of Cullinan Oncology worth $4.33M as of Q2 2026.
  • Cullinan Oncology was a new Adage Capital Partners position in Q2 2026.
  • Cullinan Oncology made up 0.01% of Adage Capital Partners's portfolio in Q2 2026, its #823 holding.
  • Adage Capital Partners first reported a position in Cullinan Oncology in Q1 2021 and has held it in 9 quarters since.
  • Adage Capital Partners's Cullinan Oncology position peaked at $38.9M in Q2 2024.
  • 183 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.